샘플 요청 목록

 카트 문의
시장보고서
상품코드
1792938

세계의 인간 면역글로불린 시장

Human Immunoglobulin
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 279 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

인간 면역글로불린 세계 시장은 2030년까지 283억 달러에 달할 전망

2024년에 170억 달러로 추정되는 인간 면역글로불린 세계 시장은 2024년부터 2030년까지 CAGR 8.9%로 성장하여 2030년에는 283억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 자가면역질환 용도는 CAGR 10.7%를 기록하며 분석 기간 종료시에는 126억 달러에 달할 것으로 예측됩니다. 혈액질환 용도 분야의 성장률은 분석 기간 동안 CAGR 6.5%로 추정됩니다.

미국 시장은 46억 달러로 추정, 중국은 CAGR 14.1%로 성장 예측

미국의 인간 면역글로불린 시장은 2024년에 46억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 63억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 14.1%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 4.4%와 8.5%로 예측됩니다. 유럽에서는 독일이 CAGR 5.9%로 성장할 것으로 예측됩니다.

세계의 인간 면역글로불린 시장 - 주요 동향과 촉진요인 정리

면역 관련 질환의 확대가 인간 면역글로불린의 사용을 어떻게 형성하고 있는가?

항체가 풍부한 중요한 혈액 유래 제품인 인간 면역글로불린은 특히 면역 결핍 및 자가 면역 질환 관리와 같은 광범위한 치료 분야에서 점점 더 많이 사용되고 있습니다. 전 세계적으로 면역 관련 질환의 부담이 증가함에 따라 의료진은 면역글로불린 요법을 면역 보충 및 면역 조절 목적으로 활용하고 있습니다. 일차성 면역 결핍증은 환자가 자연적으로 충분한 항체를 생산할 수 없는 질환으로, 면역글로불린 치료의 가장 흔한 적응증 중 하나입니다. 이런 경우, 면역글로불린 수액은 생명을 위협하는 감염을 예방하고 장기적인 건강상태를 안정시키는 데 매우 중요합니다. 또한, 만성 염증성 탈수초성 다발성 신경염, 중증근무력증 등 자가면역성 신경질환의 치료에도 널리 사용되고 있으며, 과도한 면역반응을 조절하는 데 도움을 주고 있습니다. 또한, 화학요법, HIV, 골수 이식에 의한 이차성 면역결핍증도 인간면역글로불린 요법으로 관리되고 있어 그 범용성이 강조되고 있습니다. 이러한 애플리케이션에 대한 의료진과 환자들의 인식이 높아지면서 병원, 전문 클리닉, 재택의료 현장에서의 수요가 꾸준히 증가하고 있습니다. 질병에 대한 인식이 높아지고 진단 능력이 향상됨에 따라 더 많은 환자들이 이 치료법의 후보로 올바르게 인식되고 있으며, 인간 면역글로불린에 대한 임상적 신뢰가 더욱 강화되고 있습니다. 이러한 치료 범위의 확대는 면역글로불린의 의학적 의의를 높일 뿐만 아니라 지속적인 시장 성장의 토대를 마련하고 있습니다.

혈장 채취 및 정제의 기술 혁신이 공급과 안전성을 향상시키는 이유는 무엇인가?

혈장 채취 및 면역글로불린 정제의 혁신은 이러한 중요한 치료법의 신뢰성, 안전성 및 가용성을 형성하는 데 있어 획기적인 역할을 하고 있습니다. 인간 면역글로불린의 생산은 건강한 기증자로부터 혈장을 채취하는 것으로 시작되는데, 자동화된 아펠레시스 장비의 도입으로 이 공정의 효율성과 수율이 모두 향상되었습니다. 이 기계는 혈장 성분을 선택적으로 추출할 수 있어 생산량을 늘리면서 기증자의 피로를 줄일 수 있습니다. 채취된 혈장은 에탄올 분획, 크로마토그래피, 바이러스 불활성화 등의 과정을 거쳐 병원균과 불순물 제거를 위해 엄격한 정제를 거칩니다. 이러한 공정은 최종 제품의 효능을 떨어뜨리지 않으면서도 안전성을 높이기 위해 지속적으로 개선되고 있습니다. 새로운 여과 방법을 통해 제조업체는 더 높은 수준의 순도를 달성할 수 있게 되어, 수용자의 부작용 위험을 줄일 수 있게 되었습니다. 또한, 콜드체인 물류 및 포장의 혁신은 면역글로불린 제제의 안정성과 보존성을 향상시켰으며, 이는 냉장 운송에 대한 접근성이 제한적인 지역에서 특히 중요합니다. 또한, 인간 혈장이 일차적인 정보원임에는 변함이 없지만, 많은 제조업체들이 재조합 기술이나 대체 발현 시스템에 투자하고 있습니다. 이러한 발전으로 면역글로불린 공급망은 더욱 견고하고 확장 가능하며, 세계 수요 변동에 대응할 수 있는 능력을 갖추게 되었습니다. 혈장 채취 네트워크를 구축하거나 확장하려는 국가들이 늘어나고 있는 가운데, 이러한 기술은 전 세계적으로 보다 안전하고 효율적인 면역글로불린 치료를 실현할 수 있는 청사진을 제시합니다.

의료 인프라와 정책 이니셔티브는 면역글로불린 치료에 대한 광범위한 접근을 어떻게 지원하고 있는가?

인간 면역글로불린 요법에 대한 접근성은 국가 보건 의료 이니셔티브, 국제 협력 및 진화하는 상환 제도에 의해 점점 더 많이 지원되고 있습니다. 고소득 국가에서는 면역글로불린 요법이 일반적으로 공공 또는 민간 보험에 포함되어 있으며, 병원 및 외래 진료 시설에서 임상적으로 널리 사용되고 있습니다. 최근 중진국 정부도 면역글로불린이 과소 진단되는 면역 관련 질환의 치료에 유용하다는 것을 인식하고 필수 의약품 목록에 포함시키기 시작했습니다. 일부 국가에서는 수입 의존도를 낮추고 국내 생산을 통한 가용성을 높이기 위해 혈장 자급자족 프로그램을 시행하고 있습니다. 민관 파트너십과 비영리 단체는 특히 혈장 수집 및 처리 능력이 제한적이었던 지역에서 인프라 구축을 촉진하고 있습니다. 또한, 질환별 옹호 단체는 적시 진단과 장기적인 치료를 우선시하는 공평한 접근과 정책 개혁을 추진하는 데 중요한 역할을 하고 있습니다. 표준화된 치료 가이드라인과 국제 보건기구의 최신 프로토콜은 전 세계 의사들이 면역글로불린을 언제, 어떻게 사용해야 효과적인지 이해하는 데 도움을 주고 있습니다. 의료 전문가에 대한 교육 및 훈련이 개선되고 진단 도구에 대한 접근성이 향상됨에 따라 환자들은 근거에 기반한 적응증에 따라 적절한 치료를 받을 수 있게 되었습니다. 이러한 체계적인 노력으로 면역글로불린 치료에 대한 기존의 장벽이 허물어지고, 면역글로불린 치료의 적용 범위가 3차 병원뿐만 아니라 소규모 의원이나 지방 의료센터까지 확대되고 있습니다. 의료 시스템이 성숙하고 포괄적으로 발전함에 따라, 면역글로불린 사용을 지원하는 인프라는 더욱 신뢰할 수 있고, 공정하며, 세계 표준에 부합하는 치료로 발전하고 있습니다.

인간 면역글로불린 시장의 세계 확장을 촉진하는 주요 요인은 무엇인가?

인간 면역글로불린 시장의 세계 확대는 의료, 기술, 인구통계 및 전략적 요인의 결합으로 인해 수요 증가와 의료 우선순위의 진화를 반영하여 이루어지고 있습니다. 주요 촉진요인 중 하나는 선천성 및 후천성 면역 결핍의 유병률 증가, 의료 인식의 향상과 검진 능력의 향상으로 인한 진단율의 상승입니다. 노인은 감염성 질환이나 자가면역질환에 걸리기 쉽고, 면역글로불린 치료의 중요한 수혜자가 되기 때문입니다. 혈장 채취 및 분획 기술의 급속한 발전으로 보다 안정적인 공급망을 확보할 수 있게 되었습니다. 이와 함께 신속한 승인과 표준화된 안전 요구 사항으로 인해 신제품의 시장 진입이 용이해지는 등 규제 프레임워크도 더욱 강화되고 있습니다. 제약사들은 또한 재택의료를 지원하고 치료 순응도를 높이기 위해 피하 제제 및 기타 환자 친화적인 전달 시스템을 개발하는 데 주력하고 있습니다. 바이오 제약 분야의 전략적 투자와 합병은 특히 신흥 경제권에서 더 넓은 유통망과 더 깊은 시장 침투를 가능하게 하고 있습니다. 또한, 희귀질환 및 희귀질환 치료제(희귀의약품)에 대한 관심이 높아짐에 따라, 흔하지 않은 적응증에 대한 틈새 면역글로불린 치료제의 기술 혁신이 촉진되고 있습니다. 인식 개선 캠페인, 임상 교육, 정부 지원의 확대와 함께 인간 면역글로불린 시장은 전 세계적으로 지속적인 성장을 거듭하며 면역 체계에 대한 신뢰할 수 있고 효과적인 지원이 필요한 환자들에게 중요한 솔루션을 제공하고 있습니다.

부문

용도(자가면역질환 용도, 혈액질환 용도, 염증성 질환 용도, 감염성 질환 용도, 기타 용도), 최종 용도(병원 최종 용도, 진료소 최종 용도, 외래 수술 센터 최종 용도)

조사 대상 기업 사례

  • ADMA Biologics, Inc.
  • Baxter International Inc.
  • Bharat Serums and Vaccines Ltd
  • Biotest AG
  • Bio Products Laboratory Ltd(BPL)
  • CSL Behring
  • China National Pharmaceutical Group(Sinopharm)
  • GC Pharma
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kedrion Biopharma
  • LFB S.A.
  • Octapharma AG
  • Reliance Life Sciences
  • Sanquin
  • Shanghai RAAS Blood Products Co.
  • Shire(Now part of Takeda)
  • Sichuan Yuanda Shuyang Pharmaceutical Co.
  • Takeda Pharmaceutical Company Ltd.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.25

Global Human Immunoglobulin Market to Reach US$28.3 Billion by 2030

The global market for Human Immunoglobulin estimated at US$17.0 Billion in the year 2024, is expected to reach US$28.3 Billion by 2030, growing at a CAGR of 8.9% over the analysis period 2024-2030. Autoimmune Disorders Application, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach US$12.6 Billion by the end of the analysis period. Growth in the Hematology Diseases Application segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 14.1% CAGR

The Human Immunoglobulin market in the U.S. is estimated at US$4.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.3 Billion by the year 2030 trailing a CAGR of 14.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Global Human Immunoglobulin Market - Key Trends & Drivers Summarized

How Is the Expanding Scope of Immune-Related Disorders Shaping the Use of Human Immunoglobulin?

Human immunoglobulin, a vital blood-derived product rich in antibodies, is increasingly being deployed across a wide range of therapeutic areas, particularly in the management of immune deficiencies and autoimmune disorders. As the global burden of immune-related diseases grows, medical professionals are turning to immunoglobulin therapy for both replacement and immunomodulatory purposes. Primary immunodeficiency disorders, where patients lack the natural ability to produce sufficient antibodies, are among the most common indications for these therapies. In such cases, immunoglobulin infusions are crucial for preventing life-threatening infections and ensuring long-term health stability. The product is also used extensively to treat autoimmune neurological diseases such as chronic inflammatory demyelinating polyneuropathy and myasthenia gravis, where it helps to regulate an overactive immune response. Furthermore, secondary immunodeficiencies caused by chemotherapy, HIV, or bone marrow transplantation are also being managed with human immunoglobulin therapy, highlighting its versatility. The growing awareness among healthcare providers and patients regarding these applications has resulted in a steady increase in demand across hospitals, specialty clinics, and home care settings. As disease awareness rises and diagnostic capabilities improve, more individuals are being correctly identified as candidates for this treatment, further reinforcing the clinical reliance on human immunoglobulin. This expanding therapeutic scope is not only elevating the medical significance of immunoglobulin but is also laying the groundwork for sustained market growth.

Why Are Technological Advancements in Plasma Collection and Purification Enhancing Supply and Safety?

Technological innovation in plasma collection and immunoglobulin purification is playing a transformative role in shaping the reliability, safety, and availability of these vital therapies. The production of human immunoglobulin begins with the collection of plasma from healthy donors, and the introduction of automated apheresis machines has improved both the efficiency and yield of this process. These machines allow for selective extraction of plasma components, reducing donor fatigue while increasing output. Once collected, the plasma undergoes rigorous purification involving processes such as ethanol fractionation, chromatography, and viral inactivation to ensure the removal of pathogens and impurities. These steps are continually being refined to enhance safety without compromising the efficacy of the final product. New filtration methods are allowing manufacturers to achieve higher levels of purity, reducing the risk of adverse reactions in recipients. Moreover, innovations in cold-chain logistics and packaging are improving the stability and shelf life of immunoglobulin preparations, especially important in regions with limited access to refrigerated transport. Many producers are also investing in recombinant technologies and alternative expression systems, though human plasma remains the primary source. These advancements collectively ensure that the supply chain for immunoglobulin is becoming more robust, scalable, and responsive to global demand fluctuations. As more countries seek to establish or expand their plasma collection networks, these technologies provide the blueprint for safer and more efficient immunoglobulin therapies worldwide.

How Are Healthcare Infrastructure and Policy Initiatives Supporting Broader Access to Immunoglobulin Therapy?

Access to human immunoglobulin therapy is being increasingly supported by national healthcare initiatives, international collaborations, and evolving reimbursement structures. In high-income countries, immunoglobulin is generally included in public or private insurance plans, allowing widespread clinical use in hospitals and outpatient care facilities. In recent years, governments in middle-income countries have also begun integrating immunoglobulin into essential medicines lists, recognizing its value in treating immune-related conditions that often go underdiagnosed. Some nations are implementing plasma self-sufficiency programs to reduce reliance on imported products and improve availability through domestic production. Public-private partnerships and nonprofit organizations are facilitating infrastructure development, especially in regions where plasma collection and processing capacity have been historically limited. Additionally, disease-specific advocacy groups have played a crucial role in pushing for equitable access and policy reforms that prioritize timely diagnosis and long-term treatment. Standardized treatment guidelines and updated protocols from international health bodies are also helping physicians around the world understand when and how to use immunoglobulin effectively. Improvements in training and education for healthcare professionals, combined with greater access to diagnostic tools, are ensuring that patients receive appropriate therapy based on evidence-based indications. These systemic efforts are breaking down traditional barriers to immunoglobulin therapy, expanding its reach beyond tertiary hospitals to smaller clinics and rural health centers. As healthcare systems continue to mature and become more inclusive, the infrastructure supporting immunoglobulin use is becoming more reliable, equitable, and aligned with global standards of care.

What Key Factors Are Driving the Global Expansion of the Human Immunoglobulin Market?

The global expansion of the human immunoglobulin market is driven by a confluence of medical, technological, demographic, and strategic factors that reflect growing demand and evolving healthcare priorities. One of the primary drivers is the increasing prevalence of immune deficiencies, both congenital and acquired, coupled with rising diagnostic rates due to improved medical awareness and screening capabilities. An aging global population is also contributing to market growth, as elderly individuals are more susceptible to infections and autoimmune conditions, making them key beneficiaries of immunoglobulin therapy. The rapid advancement of plasma collection and fractionation technology ensures a more stable supply chain, which is essential given the high resource intensity of immunoglobulin production. In parallel, regulatory frameworks are becoming more supportive, with expedited approvals and standardized safety requirements making it easier for new products to enter the market. Pharmaceutical companies are also focusing on the development of subcutaneous formulations and other patient-friendly delivery systems that support home-based care and improve treatment adherence. Strategic investments and mergers in the biopharmaceutical sector are enabling broader distribution networks and deeper market penetration, especially in emerging economies. Additionally, the growing focus on rare diseases and orphan drug incentives is encouraging innovation in niche immunoglobulin therapies for less common indications. As awareness campaigns, clinical training, and government support continue to expand, the human immunoglobulin market is positioned for sustained global growth, offering critical solutions for patients whose immune systems require reliable, effective support.

SCOPE OF STUDY:

The report analyzes the Human Immunoglobulin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application, Other Applications); End-Use (Hospitals End-Use, Clinics End-Use, Ambulatory Surgery Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • ADMA Biologics, Inc.
  • Baxter International Inc.
  • Bharat Serums and Vaccines Ltd
  • Biotest AG
  • Bio Products Laboratory Ltd (BPL)
  • CSL Behring
  • China National Pharmaceutical Group (Sinopharm)
  • GC Pharma
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kedrion Biopharma
  • LFB S.A.
  • Octapharma AG
  • Reliance Life Sciences
  • Sanquin
  • Shanghai RAAS Blood Products Co.
  • Shire (Now part of Takeda)
  • Sichuan Yuanda Shuyang Pharmaceutical Co.
  • Takeda Pharmaceutical Company Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Human Immunoglobulin - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Primary Immunodeficiency Disorders Throws the Spotlight on Human Immunoglobulin as a Lifesaving Therapy
    • Growing Use in Autoimmune and Neurological Disorders Propels Demand for Intravenous and Subcutaneous Immunoglobulin
    • Here's the Story: Expanding Indications Beyond PID Strengthens the Business Case for Broader Immunoglobulin Utilization
    • Advancements in Plasma Fractionation Technologies Drive Supply Chain Efficiency and Product Innovation
    • Increasing Awareness and Diagnosis Rates Accelerate Demand Across Both Developed and Emerging Healthcare Markets
    • Here's How Aging Populations Fuel the Need for Immunoglobulin in Chronic Immune-Mediated Conditions
    • Plasma Collection Shortages and Donor Dependency Pose Long-Term Supply Challenges for the Immunoglobulin Market
    • Emergence of Subcutaneous Formulations Sustains Growth by Enabling Home-Based, Self-Administered Treatments
    • Global Expansion of Plasma Collection Centers Expands Addressable Supply and Geographic Market Reach
    • Improved Product Purity and Safety Profiles Drive Adoption Among Pediatric and Geriatric Patient Populations
    • Here's How Biotech Innovation Advances Recombinant Alternatives to Conventional Human-Derived Immunoglobulin
    • Rising Demand in Critical Care and Infectious Disease Management Opens New Emergency Use Scenarios
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Human Immunoglobulin Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Human Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Autoimmune Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hematology Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hematology Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Hematology Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Inflammatory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Inflammatory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Inflammatory Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Human Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Human Immunoglobulin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Human Immunoglobulin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Human Immunoglobulin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Human Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Human Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Human Immunoglobulin by Application - Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Human Immunoglobulin by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Hematology Diseases Application, Inflammatory Diseases Application, Infectious Diseases Application and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Human Immunoglobulin by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Human Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제